OBJECTIVE: To evaluate the effectiveness and safety of switching to a second or third biological agent in juvenile idiopathic arthritis (JIA) after etanercept failure. METHODS: The Arthritis and Biologicals in Children Register aims to include all Dutch JIA patients who have used biological agents. Data on the disease course were used to estimate drug survival with Kaplan-Meier and calculate adverse event (AE) rates. RESULTS: Of 307 biologically naive JIA patients who started etanercept, 80 (26%) switched to a second and 22 (7%) to a third biological agent. During 1030 patient-years of follow-up after the introduction of etanercept, 49 switches to adalimumab, 28 infliximab, 17 anakinra, four abatacept and four trial drugs were evaluated. 84% (95% CI 80% to 88%) of patients who started etanercept as a first biological agent were, after 12 months, still on the drug, compared with 47% (95% CI 35% to 60%) who started a second and 51% (95% CI 26% to 76%) who started a third biological agent. Patients who switched because of primary ineffectiveness continued the second agent less often (32%, 95% CI 12% to 53%). After etanercept failure, drug continuation of adalimumab was similar to infliximab for patients with non-systemic JIA; anakinra was superior to a second TNF-blocker for systemic JIA. AE rates within first 12 months after initiation were comparable for each course and each biological agent. CONCLUSIONS: Switching to another biological agent is common, especially for systemic JIA patients. A second (and third) agent was less effective than the first. The choice of second biological agent by the physician mainly depends on availability and JIA category.
OBJECTIVE: To evaluate the effectiveness and safety of switching to a second or third biological agent in juvenile idiopathic arthritis (JIA) after etanercept failure. METHODS: The Arthritis and Biologicals in Children Register aims to include all Dutch JIA patients who have used biological agents. Data on the disease course were used to estimate drug survival with Kaplan-Meier and calculate adverse event (AE) rates. RESULTS: Of 307 biologically naive JIA patients who started etanercept, 80 (26%) switched to a second and 22 (7%) to a third biological agent. During 1030 patient-years of follow-up after the introduction of etanercept, 49 switches to adalimumab, 28 infliximab, 17 anakinra, four abatacept and four trial drugs were evaluated. 84% (95% CI 80% to 88%) of patients who started etanercept as a first biological agent were, after 12 months, still on the drug, compared with 47% (95% CI 35% to 60%) who started a second and 51% (95% CI 26% to 76%) who started a third biological agent. Patients who switched because of primary ineffectiveness continued the second agent less often (32%, 95% CI 12% to 53%). After etanercept failure, drug continuation of adalimumab was similar to infliximab for patients with non-systemic JIA; anakinra was superior to a second TNF-blocker for systemic JIA. AE rates within first 12 months after initiation were comparable for each course and each biological agent. CONCLUSIONS: Switching to another biological agent is common, especially for systemic JIA patients. A second (and third) agent was less effective than the first. The choice of second biological agent by the physician mainly depends on availability and JIA category.
Authors: Mario Abinun; Jonathan P Lane; Mark Wood; Mark Friswell; Terence J Flood; Helen E Foster Journal: Emerg Infect Dis Date: 2016-10 Impact factor: 6.883
Authors: Franz Thiele; Ariane Klein; Daniel Windschall; Anton Hospach; Ivan Foeldvari; Kirsten Minden; Frank Weller-Heinemann; Gerd Horneff Journal: Rheumatol Int Date: 2021-02-16 Impact factor: 2.631
Authors: Hermine I Brunner; Nicolino Ruperto; Zbigniew Zuber; Caroline Keane; Olivier Harari; Andrew Kenwright; Peng Lu; Ruben Cuttica; Vladimir Keltsev; Ricardo M Xavier; Inmaculada Calvo; Irina Nikishina; Nadina Rubio-Pérez; Ekaterina Alexeeva; Vyacheslav Chasnyk; Gerd Horneff; Violetta Opoka-Winiarska; Pierre Quartier; Clovis A Silva; Earl Silverman; Alberto Spindler; Eileen Baildam; M Luz Gámir; Alan Martin; Christoph Rietschel; Daniel Siri; Elzbieta Smolewska; Daniel Lovell; Alberto Martini; Fabrizio De Benedetti Journal: Ann Rheum Dis Date: 2014-05-16 Impact factor: 19.103
Authors: Lianne Kearsley-Fleet; Rebecca Davies; Eileen Baildam; Michael W Beresford; Helen E Foster; Taunton R Southwood; Wendy Thomson; Kimme L Hyrich Journal: Rheumatology (Oxford) Date: 2016-01-04 Impact factor: 7.580
Authors: Lianne Kearsley-Fleet; Eleanor Heaf; Rebecca Davies; Eileen Baildam; Michael W Beresford; Helen E Foster; Taunton R Southwood; Wendy Thomson; Kimme L Hyrich Journal: Lancet Rheumatol Date: 2020-03-09